Pfizer, Beam Enter Exclusive Multi-Target Research Collaboration To Advance Novel In Vivo Base Editing Programs For A Range Of Rare Diseases; Beam Will Receive An Upfront Payment Of $300M, Be Eligible To Receive Future Milestone Payments Of Up To $1.05B

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!